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The objective of this paper is to review the available literature concerning the effects of subthalamic
nucleus deep brain stimulation (STN-DBS) on quality of life (QoL) and motor and depressive symptoms in
patients with Parkinson's disease (PD). These studies demonstrate that STN-DBS has an effect on QoL and
symptoms in patients with PD. There was a signiﬁcant improvement in QoL following STN-DBS
compared with no improvement after medical therapy. PD patients treated with STN-DBS had a 40
e50% improvement in motor function. Nevertheless, depressive symptoms did not reveal consistent
change.
Copyright © 2015, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Parkinson's disease (PD) is a chronic neurodegenerative disease
that places a substantial burden on patients and their families and
caregivers, as well as society. It is characterized by muscle rigidity,
resting tremor, bradykinesia, and postural instability [1]. Although
optimal pharmacological therapy with levodopa and other adju-
vant regimens can be achieved, complications associated with the
treatment of PD, such as dyskinesia and motor ﬂuctuation, inevi-
tably occur around 5 years after the initiation of therapy [2e4]. The
progressive decline in motor function and the comorbidity associ-
ated with PD negatively affect quality of life (QoL) [5]. Depression is
one of the most common psychiatric disorders in PD [6], with 35%
of patients reporting some level of depressive symptoms, including
17% with major depressive disorders and 22% with minor depres-
sion [7]. Depressive symptoms have been recognized as a major
contributor to poor QoL, poor motor and cognitive function, and
caregiver burden [8].ry, Buddihist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
. Chen).
elief Tzu Chi Foundation. PublisheSubthalamic nucleus deep brain stimulation (STN-DBS) therapy
has emerged as an additional option for PD treatment and pro-
vides PD patients with improved QoL and control of motor
symptoms. Although the precise mechanism by which deep brain
stimulation (DBS) exerts beneﬁts is still elusive, increasing evi-
dence suggests that it might involve multidisciplinary effects on
the target where afferent nerves are stimulated and neurotrans-
mitters are released [9,10]. Despite a rapid increase in the number
of studies of STN-DBS in patients with PD, there is still some
disagreement on its impact.
Clinical evaluation of PD is usually carried out by assessing a
variety of functional and mental aspects in addition to data
gathered from medical examinations. The Core Assessment Pro-
gram for Surgical Intracerebral Therapies protocol [11] recom-
mends assessment of QoL using an instrument such as a rating
scale before starting the preoperative evaluation and, thereafter, at
6 months, 1 year, and 2 years, and then every year if evaluation is
continued. Comparison of pre- and postoperative ﬁndings is
important in this group of STN-DBS patients. This review seeks to
identify studies that provide information regarding outcomes of
STN-DBS in patients with PD, and summarize and compare
changes in QoL and motor and depressive symptoms from these
studies.d by Elsevier Taiwan LLC. All rights reserved.
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2.1. Search methods
A search strategy was developed to identify published studies
on the impact of STN stimulation on QoL in patients with PD. An
expert panel was established to guide the review process. The
search for eligible studies was comprehensive and involved mul-
tiple strategies. Data were sought from published studies in English
language journals. Searches were limited to human-based studies.
An initial limited literature search of PubMed was conducted to
identify relevant keywords contained in the title, abstract, and
subject descriptions. We used Medical Subjects Headings to select
search terms. STN-DBS was ﬁrst applied for PD in 1993 [12]. Similar
strategies were used in searching other bibliographic databases
(Table 1) for relevant research articles published between 1993 and
2014. In addition, we reviewed references from articles identiﬁed in
the aforementioned searches to include any additional papers
related to outcomes of DBS that may have been missed.
We used the following terms as keywords: deep brain stimula-
tion, subthalamic nucleus stimulation, neurostimulation, quality of
life, health-related quality of life,motor symptom, nonmotor symptom,
psychiatric symptom, mood, and Parkinson's disease. The key words
used to search for publications that met the design criteria were
randomized controlled trial/s, controlled trial/s, random allocation,
and clinical trials. Figure 1 shows the ﬂow of information through
the different phases.
To identify potentially eligible articles, two authors (J.L.J. and
S.T.T.) screened the titles and abstracts obtained from the electronic
search strategy. Retrieved abstracts were further scrutinized to
include only those studies that had at least 6 months of follow-up.
In addition, authors scanned abstracts to ensure the presence of
outcome data, including pre- and postsurgical QoL scores. If a de-
cision could not be made regarding eligibility for inclusion, the full
text of the article was examined. Full length articles of all selected
abstracts were retrieved and assessed by the same reviewers for the
inclusion criteria reported below.2.2. Inclusion criteria
2.2.1. Types of studies
The selection criteria were studies restricted to randomized or
nonrandomized control trials on the effectiveness of STN-DBS for
treatment of idiopathic Parkinson's disease. Randomized controlled
trials (RCTs) provide the best possible evidence on clinical out-
comes. If ﬁltering only identiﬁed a small number of RCTs, clinical
controlled trials could also be included. The use of nonrandomized
data required careful consideration of the comparability of the
treatment and control groups in those studies. Retrieved abstracts
were further scrutinized to include only those studies with at least
6 months of follow-up.
Excluded from the review were investigations that primarily
examined factors that predicted changes in QoL and other sys-
tematic reviews relevant to this topic [13,14]. Studies documentingTable 1
Electronic databases searched.
Database searched Publication dates
PubMed 1993eNov 2014
Cochrane Library 1993eNov 2014
MEDLINE via Ovid online 1993eNov 2014
EBSCO host 1993eNov 2014
CINAHL 1993eNov 2014
CEPS þ CETD 1993eNov 2014only nonmotor outcomes (for example, cognitive function) or sur-
gical parameters (such as microelectrode recording) were not
considered in our review. We also excluded studies if the electrode
implantation site was not the subthalamic nucleus. Only articles
meeting the inclusion criteria were retained for analysis.
2.2.2. Participants
Studies of human individuals were included, and animal and
laboratory studies were excluded. There were a number of animal
and laboratory studies in this area, but the generalizability from
laboratory animal models to clinical patients is problematic.
2.2.3. Intervention
The intervention of interest was STN-DBS used to change QoL,
motor symptoms and psychiatric symptoms in patients with idio-
pathic PD.
2.2.4. Outcome measurements
2.2.4.1. QoL: Disease-speciﬁc 39-item PD questionnaire. The World
Health Organization deﬁnes QoL as “individuals' perception of their
position in life in the context of the culture and value systems in
which they live and in relation to their goals, expectations, stan-
dards, and concerns” [15]. Several QoL tools have been used in PD. A
movement disorder society task force was commissioned to rate
the psychometric quality of available QoL scales as applied to PD.
Siderowf et al [16] reported that generic instrumentsmay represent
relatively lower sensitivity to change as shown by the 36-Item
short-form health survey compared with the 39 item Parkinson's
disease questionnaire (PDQ-39).The PDQ-39 is the most thoroughly
tested and applied questionnaire for PD [17]. It has adequate psy-
chometric properties and adequately covers physical, mental, and
social domains. It is composed of 39 items grouped in eight sub-
scales: mobility, activities of daily living (ADL), emotional well-
being, stigma, social support, cognition, communication, and
bodily discomfort [18].
2.2.4.2. Motor symptoms: uniﬁed PD rating scale. PD is character-
ized bymotor symptoms. The uniﬁed PD rating scale (UPDRS) is the
most commonly used scale in the clinical study of PD.
2.2.4.3. Depressive symptoms: Beck depression inventory.
Depression is one of the most common psychiatric disorders in PD.
The Beck depression inventory is one of the most widely used in-
struments for measuring the severity of depression.
3. Results
The database search and reviewed references from included
articles yielded 39 citations published between January 1,1993, and
November 30, 2014. Articles were excluded based on information in
the title and abstract. The full texts of potentially relevant articles
were obtained for further assessment. Twenty-eight studies met
the inclusion criteria. Eight studies reported on QoL, 12 on motor
symptoms, and eight on depressive symptoms in patients with PD
after STN-DBS surgery.
3.1. STN-DBS effects on QoL
Kuehler et al [19] suggested that there is a need to determine
whether such a sophisticated and costly treatment is not only safe
and effective, but alsowhether it enhances QoL. Several RCTs of DBS
have conﬁrmed its efﬁcacy [20e23]. The end points of these trials
included QoL, mood, or the severity of motor symptoms when the
patient was not taking medication, and the number of hours per
day spent in the on state without dyskinesia. Six RCTs (1184
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Fig. 1. Literature search ﬂow diagram.
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alone were included in a meta-analysis study [24]. The results
showed that DBS signiﬁcantly improves patients' symptoms,
functionality, and QoL. QoL signiﬁcantly improved in the majority
of patients after STN-DBS [20e22,25e29]. These results are sum-
marized in Table 2. Lyons et al [30] found that the signiﬁcant im-
provements in QoL following STN-DBS were strongly correlated
with improvements in motor function, primarily with regard to
bradykinesia.
Deuschl et al [20] and Weaver et al [22] reported signiﬁcant
improvement in the PDQ-39 subscales for mobility, ADL, stigma,
and bodily discomfort at the 6-month follow-up. Another study
showed signiﬁcant improvements in mobility, ADL, and bodily
discomfort. All of these studies reported no improvement in the
social support and communication dimensions.3.2. STN-DBS improvement of motor symptoms
The cardinal clinical manifestations of PD are resting tremor,
rigidity, bradykinesia, and gait disturbance/postural instability.
According to some reports, the motor improvement induced by
STN-DBS is sustained for up to 5e8 years after surgery [3,31e38]. Aprospective, multicenter study [39] of STN-DBS was performed in
96 patients with advanced PD. At 6 months, stimulation in the off-
medication state was associated with a mean improvement of
approximately 50% in the ADL and motor scores on the UPDRS. The
beneﬁts of stimulation were conﬁrmed in a double-blind crossover
component of the study, which demonstrated a 40e50% improve-
ment in UPDRS motor scores. STN-DBS improves dopaminergic
sensitive symptoms and dyskinesia and allows for reduced drug
doses [40]. However, it may have isolatable effects on verbal
ﬂuency and related function [41]. Table 3 shows the summaries of
included studies related to motor symptoms.3.3. Inﬂuence of STN-DBS on depressive symptoms
PD is frequently accompanied by mood disturbance, with 35% of
patients reporting some level of depressive symptoms, including
19%withmajor depressive disorders [7]. One study showed that the
degree of depression and disease severity were signiﬁcantly
correlated with the QoL of PD patients.
Several studies investigating the psychiatric symptoms of pa-
tients following STN-DBS did not reveal any cognition and mood
changes [23,42,43], while others documented improvements in
Table 2
Summaries of included studies related to quality of life.
Author (y)
[Ref]
Country
Design Participant Treatment Outcome measured Results
Sobstyl et al (2014) [29]
Poland
(1) Nonrandomized, prospective
trial.
(2) Assessments were scheduled at
baseline, 1 y, & 2 y.
All 16 patients with PD were
assessed 1 y after STN-DBS& 14
were studied 2 y after surgery.
Bilateral STN-DBS PDQ-39 All dimensions of PDQ-39 as well PDQ-39
summary index score were highly signiﬁcantly
improved after 1 y. The same improvements
were visible in 2 y follow-up with the exception
of social support & communication.
Schuepbach et al (2013) [28]
Germany
France
(1) Randomized, multicenter,
parallel-group design.
(2) Assessments were scheduled at
baseline, 5 mo, 12 mo, & 24 mo.
A total of 251 patients with PD.
Neurostimulation plus medical
therapy (n ¼ 124) vs. medical
therapy alone (n ¼ 127).
STN-DBS plus medical therapy
vs. medical therapy
PDQ-39 For the primary outcome of quality of life, the
mean score for the neurostimulation group
improved by 7.8 points, & that for the medical-
therapy group worsened by 0.2 points (be-
tween-group difference in mean change from
baseline to 2 y, 8.0 points; p ¼ 0.002).
Daniels et al (2011) [27]
Germany
(1) Multicenter randomized,
controlled trial.
(2) Assessments were scheduled at
baseline & 6 mo.
A total of 121 patients with PD.
STN-DBS group (n ¼ 61).
Control group (n ¼ 60).
STN-DBS vs. best medical
treatment
(1) PDQ-39 summary index
(2) Physical composite score
of SF-36
(1) PDQ-39 summary index improved after
STN-DBS for 57% of the patients. Patients
with improvement in QoL showed signiﬁ-
cantly higher cumulative daily off time.
(2) The changes in SF-36 physical composite
score are negatively correlated with the
UPDRS dyskinesia score on at baseline, so
fewer dyskinesia are associated with
greater QoL improvement.
Williams et al (2010) [21]
UK
(1) Randomized, open-label trial.
(2) Assessments were scheduled at
baseline & 12 mo.
366 patients from 13
neurosurgical centers in the UK
were assigned to the surgery
group (n ¼ 183) or to the best
medical therapy group
(n ¼ 183).
STN-DBS (n ¼ 174) or GPi DBS
vs. best medical therapy
PDQ-39 summary index At 1 y, the mean improvement in PDQ-39
summary index score compared with baseline
was 5.0 points in the surgery group& 0.3 points
in the medical therapy group (difference 4.7,
95% CI 7.6e1.8; p ¼ 0.001).
Weaver et al. (2009) [22]
USA
(1) Randomized controlled trial.
(2) Assessments were scheduled at
baseline & 6 mo.
A total of 255 patients with PD.
Bilateral STN-DBS (n ¼ 60) or
GPi (n ¼ 61).
vs. best medical therapy
(n ¼ 134).
Bilateral STN or GPi DBS vs. best
medical therapy
PDQ-39 Compared with the best medical therapy group,
the DBS group experienced signiﬁcant
improvements in the summary measure of QoL
& on 7 of 8 PDQ-39 scores (p < 0.001).
Schüpbach et al (2007) [26]
France
(1) Prospectively randomized.
Matched for age, duration,
& severity of disease, &
impairment in
socioprofessional functioning.
(2) Assessments were scheduled at
baseline & 18 mo.
A total of 20 patients with PD.
Patients were assigned to
undergo bilateral STN-DBS
(n ¼ 10) or receive medical
treatment (n ¼ 10).
Bilateral STN-DBS vs. optimized
medical treatment
PDQ-39 QoL was improved by 24% in surgical & 0% in
nonsurgical patients (p < 0.05).
Deuschl et al (2006) [20]
Germany
Austria
(1) Unblinded trial with a
randomized-pairs design.
(2) Assessments were scheduled at
baseline & 6 mo.
78 pairs of patients (n ¼ 156
patients) with PD were
assigned to treatment.
Bilateral STN-DBS
vs. best medical therapy
(1) PDQ-39 summary index
(2) SF-36 physical & mental
summary scores
For the neurostimulation group, the PDQ-39
summary index score was 41.8 ± 13.9 at base-
line & 31.8 ± 16.3 at 6 mo. In the medication
group, the PDQ-39 score was 39.6 ± 16 at
baseline& 40.2 ± 14.4 at 6 mo. The results show
an improvement of ~25% in the neuro-
stimulation group compared with almost no
change in the medication group.
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Neurostimulation also resulted in a 22%
improvement in the SF-36 physical summary
score.
Just & Ostergaard (2002) [25]
Denmark
(1) Nonrandomized, controlled
prospective trial.
(2) Assessments were scheduled at
baseline (T0), 3 mo (T3),& 6 mo
(T6).
A total of 24 patients with PD.
STN-DBS (n ¼ 11) & similar
group of patients awaiting sur-
gery (n ¼ 13).
STN-DBS
vs. nonsurgery
PDQ-39 The PDQ-39 scores from T0 to T3, the surgery
group demonstrated signiﬁcant improvement
for subscales mobility, ADL, & bodily discom-
fort, in addition to signiﬁcant improvement by
14.0 points in the PDQ-39 summary index. From
T0 to T6, the surgery group improved 16.1
points. The nonsurgery group demonstrated no
signiﬁcant changes in PDQ-39 summary index
or any of the subscales from T0 to T3 or from T0
to T6.
ADL¼ activity of daily living; DBS¼ deep brain stimulation; GPi¼ globus pallidus interna; PD¼ Parkinson's disease; PDQ-39¼ Parkinson's disease questionnaire-39; QoL¼ quality of life; Ref¼ reference; SF-36¼ short form-36;
STN ¼ subthalamic nucleus.
Table 3
Summaries of included studies related to motor symptoms.
Author (y)
[Ref]
Country
Design Participant Treatment Outcome measured Results
Jiang et al (2015) [40]
Taiwan
(1) Prospective study.
(2) Assessments were
scheduled at baseline,
1y, & 5 y.
A total of 41 patients with
PD.
Bilateral STN-DBS (1) UPDRS
(2) SEADL
When compared to the preoperative baseline
off-medication condition, signiﬁcant improve-
ments were observed in the UPDRS Parts I, II, III,
& IV, & SEADL (p < 0.001) scores 1 y after STN-
DBS; 5 y after STN-DBS, improvements in
UPDRS scores were observed only for Parts II, III,
& IV (p < 0.001).
Harati & Muller (2013) [41]
Germany
(1) Prospective study.
(2) Assessments were
scheduled at baseline,
12 mo, & 18 mo.
A total of 20 patients with
PD.
Bilateral STN-DBS (1) General cognitive screening
(2) Memory
(3) Language
(4) Visuospatial abilities
(1) There was a signiﬁcant decline of both
semantic & phonemic verbal ﬂuency & a
mild trend for a deterioration of verbal
memory after DBS.
(2) The general cognitive screening &
visuospatial abilities remained changed.
Moro et al (2010) [37]
Canada
France
Spain
Sweden
Germany
Italy
UK
The Netherlands
(1) Prospective
multicenter study.
(2) Randomized
double-blind evalua-
tion with cross-over on
the 2nd day of the 3-mo
follow-up & unblinded
assessments at 1 mo,
51 consecutive patients
with PD were assessed.
Bilateral STN-DBS (n ¼ 35)
& GPi-DBS (n ¼ 16)
(1) UPDRS
(2) Levodopa dosage
(1) STN- & GPi-DBS were signiﬁcantly effective
in improving the motor UPDRS scores (STN,
p < 0.0001, 45.4%; GPi, p ¼ 0.008, 20.0%)
compared with off-stimulation, regardless
of the sequence of stimulation. In open
assessment, both STN- & GPi-DBS signiﬁ-
cantly improved the off-medication UPDRS-
motor when compared with before surgery
(STN, p < 0.001, 50.5%; GPi, p ¼ 0.002,
(continued on next page)
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Table 3 (continued )
Author (y)
[Ref]
Country
Design Participant Treatment Outcome measured Results
6 mo, & 12 mo follow-
up.
(3) A subsequent extension
of the study was
performed to obtain
long-term data (3e4 y
& 5e6 y)
35.6%). Dyskinesias & ADL were signiﬁ-
cantly improved in both groups.
(2) Anti-PD medications were signiﬁcantly
reduced only in the STN group.
Fasano et al.-
(2010) [38]
Italy
(1) Prospective study.
(2) Assessments were
scheduled at baseline,
3 y, 5 y, & 8 y.
20 consecutive patients
with PD were assessed.
Bilateral STN-DBS (1) UPDRS
(2) Levodopa dosage
(1) The overall motor improvement reported at
5 y (55.5% at UPDRSdmotor part, p < 0.001
compared with baseline) was only partly
retained 3 y later (39%, p < 0.001, compared
with baseline; 16.5%, p < 0.01, compared
with 5 y), with differential effects on motor
features: speech did not improve& postural
stability worsened (p < 0.05).
(2) The preoperative levodopa equivalent daily
dose was reduced by 58.2% at 5 y& by 60.3%
at 8 y. In spite of subtle worsening of motor
features, a dramatic impairment in
functional state (56.6% at UPDRS-ADL,
p < 0.01) emerged after the 5th y of
stimulation.
Piboolnurak et al (2007) [36]
Canada
(1) Patients were assessed
in a nonblinded
fashion before & after
the surgery.
(2) Assessments were
scheduled at baseline,
3 y, & 5 y.
33 consecutive patients
with PD were assessed.
Bilateral STN-DBS (1) Levodopa response
(2) UPDRS
Levodopa response signiﬁcantly decreased
postoperatively by 31.1% at 3 y & 32.3% at 5 y,
possibly related to the reduction in medication
requirement, direct STN stimulation effect, or
PD progression. STN-DBS alone signiﬁcantly
improved motor scores (37.2% at 3 y & 35.1% at
5 y) & ADL scores (27.1% at 3 y & 19.2% at 5 y).
Rodriguez-Oroz et al (2005) [34]
Spain
Canada
Germany
France
Italy
UK
(1) Prospective
multicenter study.
(2) Assessments were
scheduled at baseline
& 3e4 y.
A total of 69 patients with
PD.
STN-DBS (n ¼ 49) & GPi-
DBS (n ¼ 20)
UPDRS Stimulation of the STN or GPi induced a
signiﬁcant improvement (50% & 39%;
p < 0.0001) of the off-medication UPDRS-III
score at 3e4 y with respect to baseline. Stimu-
lation improved cardinal features & ADL
(p < 0.001 & p < 0.02 for STN & GPi, respec-
tively) & prolonged the “on” time spent with
good mobility without dyskinesias (p < 0.001).
Comparison of the improvement induced by
stimulation at 1 y with 3e4 y showed a signif-
icant worsening in the “on” medication motor
states of the UPDRS-III, ADL& gait in both STN&
GPi groups, & speech & postural stability in the
STN-treated group.
Schüpbach et al (2005) [35]
France
(1) Prospective study.
(2) Assessments were
scheduled at baseline,
6 mo, 24 mo, & 60 mo.
37 consecutive patients
with PD were assessed.
Bilateral STN-DBS UPDRS 6 patients died& 1 patient was lost to follow up.
5 y after neurosurgery: (1) UPDRS II was
improved by stimulation of the STN by 40% (off
drug) & 60% (on drug); (2) parkinsonian motor
disability (UPDRS III) was improved by 54% (off
drug) & 73% (on drug); & (3) the severity of
levodopa related motor complications was
decreased by 67% & the levodopa daily doses
were reduced by 58%.
Krack et al (2003) [3]
France
(1) Prospective study. 43/49 patients with PD
were assessed 1 y after
STN-DBS & 42/49 were
Bilateral STN-DBS UPDRS As compared with baseline, the patients' scores
at 5 y for motor function while off-medication
improved by 54% (p < 0.001) & those for ADL
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(2) Assessments were
scheduled at baseline,
1 y, 3 y, & 5 y.
studied 3 y & 5 y after
surgery.
improved by 49% (p < 0.001). Speech was the
only motor function for which off-medication
scores did not improve. On-medication aki-
nesia, speech, postural stability, & freezing of
gait worsened between y 1 & y 5 (p < 0.001 for
all comparisons).
The DBS for PD Study Group (2001) [39]
Spain
France
Canada
Italy
USA
Germany
UK
Australia
(1) Prospective, double-
blind, crossover, multi-
center study.
(2) Assessments were
scheduled at baseline,
1 mo, 3 mo, & 6 mo.
A total of 134 patients with
PD.
Bilateral STN-DBS (n ¼ 96)
& GPi-DBS (n ¼ 38)
UPDRS (1) 3 mo after surgery, evaluations
demonstrated that stimulation of the STN-
DBS was associated with a median
improvement in the motor score (as
compared with no stimulation) of 49%, &
the GPi-DBS with a median improvement of
37% (p < 0.001 for both comparisons).
(2) Between the preoperative & 6-mo visits,
the percentage of time during the day that
patients had good mobility without invol-
untary movements increased from 27% to
74% (p < 0.001) with STN-DBS & from 28%
to 64% (p < 0.001) with pallidal stimulation.
Moro et al (1999) [32]
Italy
(1) Prospective study.
(2) The average follow-up
was 16.3 ± 7.6 mo.
7 consecutive patients with
PD were assessed.
Bilateral STN-DBS (1) UPDRS,
(2) SEADL
Compared with the presurgical condition, off-
drug UPDRS motor
scores improved by 41.9% on the last visit
(p ¼ 0.0002), UPDRS ADL scores improved by
52.2% (p ¼ 0.0002), & the SEADL improved by
213% (p ¼ 0.0002).
Kumar et al (1998) [33]
Canada
(1) Double-blind,
prospective study.
(2) Assessments were
scheduled at baseline,
6 mo, & 12 mo.
7 consecutive patients with
advanced PD were
assessed.
Bilateral STN-DBS 1. UPDRS (1) In themedication-off state, improvement in
mean total UPDRS motor score by 58%.
(2) In the medication-on state, UPDRS motor
score improved 41% compared with before
surgery.
(3) ADL were improved while off medication
30%, & levodopa-induced dyskinesias were
reduced 83% while total drug dosage was
decreased 40%.
Limousin et al (1995) [31]
France
(1) The 1st demonstration
in human beings by
the subthalamic nuclei
in PD patients.
(2) Assessments were
scheduled at baseline
& 3 mo.
3 patients with PD were
assessed.
Bilateral STN-DBS UPDRS (1) UPDRS PartⅡ-ADL scores had improved by
58e88% & UPDRS Part Ⅲ-motor scores by
42e84%.
ADL ¼ activity of daily living; DBS ¼ deep brain stimulation; GPi ¼ globus pallidus interna; PD ¼ Parkinson's disease; Ref ¼ reference; SEADL ¼ Schwab & England Activities of Daily Living Scale; STN ¼ subthalamic nucleus;
UPDRS ¼ Uniﬁed Parkinson's Disease Rating Scale.
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Table 4
Summaries of included studies related to depressive symptoms.
Author (y)
[Ref]
Country
Design Participant Treatment Outcome measured Results
Pinsker et al (2013) [49]
Germany
(1) Prospective study.
(2) Assessments were
scheduled at baseline &
mean follow-up of 37 mo.
A total of 65 PD patients
underwent implantation of
DBS.
(43 STN, 10 GPi, 12 VIM)
STN-DBS
GPi-DBS
VIM-DBS
Neuropsychiatric inventory Depression was the most common psychiatric
side-effect after DBS, occurring in 47.7% of all
patients (31/65 patients), without signiﬁcant
preference to a speciﬁc target (STN: 42%, GPi:
60%, VIM: 58%).
Okun et al
(2009) [23]
USA
(1) Nonrandomized,
prospective trial.
(2) Assessments were
scheduled at baseline &
7 mo.
52 patients were randomized to
unilateral STN- or GPi-DBS.
45 patients (23 GPi, 22 STN)
completed the protocol.
Unilateral STN- or GPi-DBS. Visual analog mood scale (1) The study revealed no difference between
STN- & GPi-DBS in the change of co-
primarymood& cognitive outcomes pre- to
post-DBS in the optimal setting
(2) Patients in both targets were less happy,
less energetic, & more confused when
stimulated ventrally.
Witt et al (2008) [45]
Germany
(1) Randomized, prospective
study.
(2) Assessments were
scheduled at baseline &
6 mo.
(1) 123 patients had
neuropsychological &
psychiatric examinations to
assess the changes
(2) 60 patients were randomly
assigned to receive STN-
DBS & 63 patients to have
best medical treatment.
Bilateral STN-DBS vs. best
medical therapy
(1) Cognitive functioning.
(2) Executive function,
depression, anxiety,
psychiatric status, manic
symptoms, & QoL
STN-DBS does not reduce overall cognition or
affectivity, although there is a selective decrease
in frontal cognitive functions & an
improvement in anxiety in patients after the
treatment. These changes do not affect
improvements in QoL.
Heo et al (2008) [43]
Korea
(1) Prospective study.
(2) Assessments were
scheduled at baseline,
6 mo, 12 mo.
46 consecutive patients with PD Bilateral STN-DBS BDI BDI was not signiﬁcantly changed.
Zibetti et al (2007) [42]
Italy
(1) Prospective study.
(2) Assessments were
scheduled at baseline,
12 mo, & 24 mo.
36 consecutive patients with PD Bilateral STN-DBS Nonmotor symptoms No signiﬁcant variations were detected in
intellectual impairment, depression, thought
disorders, motivation, falling unrelated to
freezing, nausea, orthostatic hypotension, &
urological dysfunction.
Kalteis et al (2006) [47]
Australia
(1) Prospective study.
(2) Patients were assessed 3
times prior to surgery & at
3 wk, 9 wk, 3 mo, 6 mo, &
12 mo after surgery.
33 consecutive patients with
PD.
Bilateral STN-DBS (1) BecheRafaelsen
melancholia scale
(2) Proﬁle of mood states
(3) BDI
(4) Stateetrait anxiety
inventory
Signiﬁcant improvements in depression,
anxiety, psychological symptoms & distress
after surgery.
Drapier et al (2005) [46]
France
(1) Prospective study.
(2) Assessments were
scheduled at baseline &
12 mo.
27 consecutive patients with PD Bilateral STN-DBS (1) UPDRS
(2) PDQ-39
(3) SF-36
(1) Using clinician's based rating scale (UPDRS),
bilateral STN DBS showed signiﬁcant
improvement in PD patients at 12-mo
follow-up.
(2) Using patient's self-assessment scales
(PDQ-39& SF-36), the physical items of QoL
signiﬁcantly improved, whereas mental
items such as emotional well-being, social
support, cognition, & communication
showed no improvement.
Funkiewiez et al (2004) [44]
France
(1) Prospective study.
(2) Assessments were
scheduled at baseline, 1 y,
& 3 y.
77 consecutive patients with
PD.
7 patients died or were lost for
follow up.
Bilateral STN-DBS (1) BDI
(2) Reports of the behavioral
changes
(1) Depression improved whereas apathy &
thought disorders worsened.
(2) Major behavioral changes were 2 transient
aggressive impulsive episodes, 1 suicide, 4
suicide attempts, 1 permanent apathy, 1
transient severe depression, 4 psychoses (1
permanent),& 5 hypomania (1 permanent).
BDI¼ Beck depression inventory; DBS¼ deep brain stimulation; GPi¼ globus pallidus interna; PD¼ Parkinson's disease; PDQ-39¼ Parkinson's disease questionnaire-39; QoL¼ quality of life; Ref¼ reference; SF- 36¼ short form
36 health survey questionnaire; STN ¼ subthalamic nucleus; UPDRS ¼ Uniﬁed Parkinson's Disease Rating Scale; VIM ¼ ventral intermediate nucleus.
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anxiety [44,45]. Using a clinician-based rating scale, Drapier et al
[46] reported that PD patients showed signiﬁcant improvement 12
months after bilateral STN-DBS. Kalteis et al [47] found signiﬁcant
improvements in depression, anxiety, psychological symptoms,
and distress after STN-DBS. The direct antidepressive mechanism is
probably associated with the impact of STN-DBS on the medial
forebrain bundle and stimulation of the limbic system, and indi-
rectly from improvement in motor functions [48]. By contrast,
depression was the most common psychiatric side effect after DBS,
occurring in 47.7% of all patients (31/65 patients), without signiﬁ-
cant preference for a speciﬁc target (subthalamic nucleus, 42%;
globus pallidus, 60%; ventral intermedius nucleus, 58%). These re-
sults are summarized in Table 4. Preoperative evaluation for
depressive symptom is crucial to identify patients who are at spe-
ciﬁc risk of psychiatric complications [49].
4. Applications of the review
The present ﬁndings contribute to the ﬁeld's understanding of
improvements in QoL and clinical features as health care pro-
fessionals prepare explanations of STN-DBS for PD patients.
Gronchi-Perrin et al [50] found that when the same patients were
assessed retrospectively using the same questionnaire, no signiﬁ-
cant changes in QoL emerged, thus showing a postoperatively
modiﬁed perception of the preoperative level of general func-
tioning. In other words, PD patients tended to overestimate their
preoperative functioning when asked about it after successful STN-
DBS. This review collected prospective cohort studies to evaluate
changes in QoL. The ﬁndings of this review will be useful to
improve evaluation systems and particularly to unify evaluation
criteria among patients having STN-DBS surgery. Lastly, we hope
that it will pave the way for clinical research projects that will help
consolidate the study of QoL and mood status of PD patients, and
not just assess their physical symptoms. Martínez-Martin [51]
highlighted the following: (1) QoL assessment contributes to a
better understanding of the disease's consequences, and its treat-
ment, on the patient, and thus helps in decision making; (2) QoL
evaluations reﬂect the point of view of patients (who may disagree
with the clinical ratings); (3) although usually correlated, QoL may
not be equated with disability; and (4) many relevant aspects
related to the emotional and psychosocial well-being of patients
cannot be evaluated appropriately using clinical methods. Health
care professionals can be more attuned to the visible and invisible
manifestations of PD that are associated with motor and nonmotor
symptoms through the incorporation of a multidisciplinary
assessment to identify treatment effects in persons living with PD.
5. Limitations of the review
Wemay have missed some studies as our literature research was
restricted to a search of only a few databases. There were a variety of
methodological weaknesses in the studies in this review. These lim-
itations included small sample sizes, limited information on the
setting of the study and qualiﬁcations and training of the in-
vestigators, and a lack of assessment of the reliability and validity of
the outcome measures. A more general limitation of this approach is
that several studies reporting only a small sample favored Type-II
errors, although most of the interventions demonstrated a signiﬁ-
cant effect. Another limitation of this review is thatonly accepted full-
paper studies were reviewed. This decision was made for practical
reasons based on the need for detailed, original study data to conduct
a complete review. It is acknowledged that inclusion of these studies
may have inﬂuenced the ﬁndings of this review. Furthermore, the
majority of studies did not report intention-to-treat analysis and/orthe last observation carried forward analysis. Moreover, it is not al-
ways possible to retrieve all eligible evidence on a given topic, as
many studies never get published. The nonpublication of study re-
sults is of great importance because it may distort the evidence base
for clinical decisionmaking. This highlights the need for replication of
studies to evaluate fully the effectiveness of STN-DBS.
6. Suggestions
Evaluation after surgery is of paramount importance. Careful
follow-up observation is recommended to look for neurological
deﬁcits or procedure-related complications and to modify phar-
macological treatment. This review demonstrate that QoL and
motor and depressive symptoms can be assessed in clinical prac-
tice. Long-term follow-up studies have demonstrated that motor
score improvements are maintained over baseline, but diminish
over 5 years following STN-DBS [41]. Longitudinal long-term
follow-up studies of QoL are needed to review the stability of
these results along the chronic course of PD. In addition, PD is a
complex, multifaceted chronic illness that affects multiple clinical
domains. Examination of potential moderating effects between the
predictor variables is needed.
7. Conclusion
STN-DBS leads to signiﬁcant improvement in QoL as well as
motor symptoms in patients with PD after surgery. However,
depressive symptoms did not reveal consistent change. Use of QoL
and depressive symptommeasurement scales should be an integral
part of the clinical protocol for patients admitted to a Parkinson's
disease surgical program. This would help identify symptoms that
affect the overall health status of PD patients other than just
physical symptoms.
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